Navigation Links
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
Date:11/6/2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that data relevant to betrixaban, the company's novel oral Factor Xa inhibitor and PRT060128, its novel ADP receptor antagonist, will be presented at the American Heart Association (AHA) Scientific Sessions 2008. The conference will be held at the Ernest N. Morial Convention Center in New Orleans, LA during November 8-12, 2008.

"We have important data being presented at AHA that demonstrate the potential of our differentiated Phase II compounds that address major unmet needs in preventing and treating thrombosis," said Charles Homcy, M.D., president and chief executive officer of Portola. "In particular, data from Dr. Paul Gurbel show how our antiplatelet agent may be effective in a high percentage of patients who do not respond adequately to clopidogrel, the current standard of care. Additionally, data being presented will show that our two Phase II agents, PRT060128 and betrixaban, our oral once-daily FXa inhibitor, may work in combination to inhibit thrombosis without raising bleeding risk. Together these data highlight some of the unique properties of our lead antithrombotic compounds."

Following are the details on each poster presentation.

Monday, November 10

Poster Title: "Combination of Direct Acting FXa Inhibitor and P2Y12

Antagonist at Non-Effective Doses Provides Significant Inhibition of

Arterial Thrombosis"

Patrick Andre et al

Time: 9:00 a.m. - 5:00 p.m.

Hall A-B1, Poster Board B129

Wednesday, November 12

Poster Title: "Oral Dosing of PRT060128, a Novel Direct-acting,

Reversible P2Y12 Antagonist Overcomes High Platelet Reactivity in

Patients Non-responsive to Clopidogrel Therapy"

Paul A. Gurbel et al

Time: 9:00 a.m. - 5:00 p.m.

Hall A-B1, Poster Board C6

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http://www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):